| First Author | Dmitrieva-Posocco O | Year | 2022 |
| Journal | Nature | Volume | 605 |
| Issue | 7908 | Pages | 160-165 |
| PubMed ID | 35477756 | Mgi Jnum | J:330252 |
| Mgi Id | MGI:7367056 | Doi | 10.1038/s41586-022-04649-6 |
| Citation | Dmitrieva-Posocco O, et al. (2022) beta-Hydroxybutyrate suppresses colorectal cancer. Nature 605(7908):160-165 |
| abstractText | Colorectal cancer (CRC) is among the most frequent forms of cancer, and new strategies for its prevention and therapy are urgently needed(1). Here we identify a metabolite signalling pathway that provides actionable insights towards this goal. We perform a dietary screen in autochthonous animal models of CRC and find that ketogenic diets exhibit a strong tumour-inhibitory effect. These properties of ketogenic diets are recapitulated by the ketone body beta-hydroxybutyrate (BHB), which reduces the proliferation of colonic crypt cells and potently suppresses intestinal tumour growth. We find that BHB acts through the surface receptor Hcar2 and induces the transcriptional regulator Hopx, thereby altering gene expression and inhibiting cell proliferation. Cancer organoid assays and single-cell RNA sequencing of biopsies from patients with CRC provide evidence that elevated BHB levels and active HOPX are associated with reduced intestinal epithelial proliferation in humans. This study thus identifies a BHB-triggered pathway regulating intestinal tumorigenesis and indicates that oral or systemic interventions with a single metabolite may complement current prevention and treatment strategies for CRC. |
